- FDA expected to recommend that same company’s booster is used
- Agency considers whether mix-and-match should be case by case
The U.S. Food and Drug Administration is poised to clear the use of a Covid-19 booster from a different manufacturer than the one that supplied a patient’s original inoculation, according to people familiar with the matter.
The FDA is still considering the scope of the measure, including whether to allow the widespread mixing and matching of vaccines or whether to narrow the parameters of use, the people said, speaking on condition of anonymity before any announcement.
The FDA declined to comment and it’s not clear when a decision will be announced. Allowing mixing-and-matching would be the agency’s first such clearance for coronavirus vaccines.
While the scope remains under discussion and may come with restrictions, the recommendation is expected to apply across all vaccine brands.
For instance, that means someone who originally received
Mixing and matching would allow providers to stock fewer vaccines and more easily provide boosters to patients who had different initial inoculations.
The New York Times earlier reported that the FDA is planning to allow mixing and matching.
Preliminary results of a U.S. government-sponsored trial found that mixing Covid vaccines produces as much or more antibodies as using the same shot as a booster.
The findings were discussed at an FDA advisory panel meeting on Friday. While no formal vote was taken, many committee members said mixing and matching should be allowed.
--With assistance from
To contact the reporter on this story:
To contact the editors responsible for this story:
Justin Blum, John Harney
© 2021 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.